Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.
  • Page:
  • 1
  • 2
  • 3
  • 4

Sphere Medical (SPHR)     

Ruthbaby - 06 May 2012 08:06

Chart.aspx?Provider=EODIntra&Code=SPHR&SChart.aspx?Provider=Intra&Code=SPHR&SizeSphere Medical has 141,757,872 Ordinary Shares of nominal value £0.01 each in issue.


The Wales Life Sciences Investment Fund 25,000,000 17.64%

Woodford Patient Capital Trust Plc 23,125,000 16.31%

LSP Life Sciences Fund 10,904,000 7.69%

Ortho-Clinical Diagnostics 8,141,250 5.74%

Fidelity Worldwide Investments 6,264,649 4.42%

Octopus Investments 6,250,000 4.41%

Ruffer LLP 5,653,895 3.99%

Royal London Asset Management 5,624,185 3.97%

Herald Investment Management 4,711,965 3.32%


Chart.aspx?Provider=EODIntra&Code=SPHR&S


Should be an exciting year ahead with developments.
Anybody had a look at this company?

Ruthbaby - 11 Mar 2016 16:37 - 44 of 71

Woodford still buying...27% now..
Nice rise again today.....

CC - 11 Mar 2016 17:43 - 45 of 71

I think there's only you and me on this one Ruth. Can't say it's my best trade at least my loss is now in the recoverable area.

Rumors circulating of a bid to which I give no credibility whatsoever.

To my mind the rise is something more to do with all the sellers who didn't believe in the product have now managed to sell their shares and are no longer competing with each other day after day pushing the price down endlessly.

Whoever sold 3.2m shares at 4.5p on the day of the Finals now looks a bit foolish

Ruthbaby - 11 Mar 2016 18:06 - 46 of 71

I agree.....
I have noted that some large trades went through late this afternoon....
I believe this has finally turned a corner.....I am grateful to Woodford fund coming on board, when they did...
Have a good weekend...and hopefully a better next week.

skinny - 12 Mar 2016 10:18 - 47 of 71

CC - some are watching :-)

kimoldfield - 12 Mar 2016 14:10 - 48 of 71

😎👀 😀

Ruthbaby - 13 Mar 2016 20:59 - 49 of 71

Well my own feelings on the sudden rise is probably a speedier approval for the Proxima 4. I feel that would trigger an announcement on the WW distribution deal...which could be a good deal...if our main shareholders have any say in the matter now...
Good luck for the week a head...as well as those watching...
;-)

CC - 14 Mar 2016 13:05 - 50 of 71

It's still going vertical - I guess there must be something driving it as we have buyers at these levels who seem more than willing to soak up the short term traders stock

CC - 14 Mar 2016 13:13 - 51 of 71

Apparently an article running tomorrow in the Cambridge news. I'd be surprised if it says anything that's not already known

Ruthbaby - 15 Mar 2016 07:50 - 52 of 71

Are we due profit taking today after near 100% increase from recent lows?
Or will we continue on our merry way to 16p and last year's open offer price?

CC - 23 Mar 2016 20:01 - 53 of 71

Woodford now up to 28%, which is interesting as he bought the last lot at 9.5p and therefore this lot must have been between 10 and 15. I'd suggest mostly 12.5 as we had alot of volume at this price yesterday.

The fact he's buying at 12.5p suggests... well based on today's trades and the price the MM are willing to give me for a volume hugely over NMS, suggests he's still collecting.

Top few holdings are:
Woodford 28.0%
Wales LS 17.6%
LSP 7.7%
OCD 5.7%
Octopus 4.4%
Ruffer 4.0%
RLAM 4.0%
Directors 0.8%

So that's 72.5%

According to recent records TDW,HL,Share Centre,Barclays most representing PI's have another 6.1%

I can name a few more below 3% but perhaps they've sold in the last few weeks. Parkway Tech had 2.4% as of 25.02, Opportunities EIS had 2.3% and City Financial 2.3%.

My point? The free float is becoming incredible tight and sooner the only shareholders left will be those too stubborn to sell as they are interested to see how this plays out.

Ruthbaby - 26 Mar 2016 18:33 - 54 of 71

Well I can be included in that group....
I noticed on another BB, that the CEO of SPHR is holding a presentation this week..organized by Share Magazine... We may begin to get some press.....
I have followed Woodford's investment strategy over the years and it would seem he positions himself to be the king maker......
So in that regard I view his buying as most positive indeed. He will not bid (himself) for the company but will be in prime position to decide the future as when he feels the time is right to sell.
I would imagine he may have had talks about the next evolutionary step of the company with other parties already.......

Ruthbaby - 08 Jun 2016 20:56 - 55 of 71

Nothing new there....

Ruthbaby - 05 Sep 2016 15:28 - 56 of 71

Company awaiting CE approval for Proxima 4. Major teaching hospital in Belgium now a customer along with a distributorship for Italy....Sp looking up....

CC - 06 Sep 2016 13:44 - 57 of 71

Price turned post Brexit and then big rise as an order for P3 came through. MM's have been squeezed for stock for over a week. Now around resistance and a few sellers appearing.

MACD's look interesting

Chart.aspx?Provider=EODIntra&Code=SPHR&S

Ruthbaby - 06 Sep 2016 22:05 - 58 of 71

All indicators have turned positive and the company seems to "different" now.
Liquidity is a problem at the moment......This CE marking surely can not be far off now?

Ruthbaby - 01 Oct 2016 07:41 - 59 of 71

Proxima 4 has received CE approval.
Launching before 2016 end......
Great news!!!!

Bullshare - 14 Oct 2016 10:59 - 60 of 71

Shares Investor Evenings showcase presentations from leading companies bringing them together in one room.

 - Directors present their latest plans regarding development and growth

 - An opportunity to talk directly to the companies and personally put forward your questions

 - The chance to network with other attendees over drinks and canapés - private investors, wealth managers, fund managers and financial institutions

Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Thursday 27th October 2016

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• Paul Atherley, MD - Berkeley Energia (BKY)
• Michael Hunt, CFO - ReNeuron Group (RENE)
• Dr Wolfgang Rencken, CEO - Sphere Medical (SPHR)
+ More to be announced
20.30 
Drinks reception and canapés
21.30 
Close
Attendance is free, but spaces are limited. Register now to secure your place!
Berkeley Energia (BKY)
Berkeley Energia (BKY) 

Berkeley Energia Limited (BKY AIM/ASX) is a high impact, clean energy company focussed on bringing its wholly owned Salamanca project into production, commencing initial development in mid-2016.

The world class uranium project is being developed in an historic mining area in western Spain, about three hours west of Madrid. Following recent ministerial approval, the Company has now received all the European Union and National level approvals required for the initial development.

The project will generate measurable social and environmental benefits in the form jobs and skills training in a depressed rural community. It will also make a significant contribution to the security of supply of Europe’s zero carbon energy needs, where Euratom recently rated “lack of investment in new mines” as the number one risk facing European utilities.”

ReNeuron Group (RENE)
ReNeuron Group (RENE) 

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. 

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.

Sphere Medical (SPHR)
Sphere Medical (SPHR) 

Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs.

Sponsored by:
AJ Bell Youinvest
Shares

Bullshare - 01 Mar 2017 10:20 - 61 of 71

Come along to one of our well know Shares Investor Evenings where you will have the chance to listen and talk to directors of dynamic listed companies. At this event  on 23 March we have Directors from Sound Energy, Sphere Medical and Valirx.

 - Listen to Directors present their latest plans regarding development and growth of their business

 - Talk directly to the companies, get to know the Directors and personally put forward your questions

 - Network with other attendees including private investors, wealth managers, fund managers and financial institutions over drinks and canapés

Who Should Attend?

The evening exposes investors to companies and funds across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Thursday 23rd March 2017

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:
18.00 
Registration and coffee
18.30 
Presentations
• James Parsons, CEO - Sound Energy (SOU)
• Dr Wolfgang Rencken, CEO - Sphere Medical (SPHR)
• Dr. George Morris, Chief Operations Officer - Valirx (VAL)
+ More to be announced
20.30 
Drinks reception and canapés
21.30 
Close
Sound Energy (SOU)
Sound Energy (SOU) 

Sound Energy is a well-funded African and European upstream gas company, listed on AIM, with a recent significant discovery in Morocco, a cornerstone investor, a strategic partnership with Schlumberger (one of the largest companies in our sector) and a potentially transformational drill programme.

We are pursuing an onshore gas strategy underpinned by strong European gas fundamentals, which is proving very robust to the current oil price environment and to an increasingly carbon-conscious world (where gas is, rightly, seen as a cleaner alternative to coal and oil).

Sphere Medical (SPHR)
Sphere Medical (SPHR) 

Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs.

Valirx (VAL)
Valirx (VAL) 

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.

Sponsored by:
AJ Bell Youinvest
PrimaryBid

Ruthbaby - 16 Mar 2017 21:17 - 62 of 71

I really am not sure if anything new will be mentioned at this presentation. However there is an improved appetite for the latest Proxima device. Blood saving alone make it an interesting device to have at least one on an ICU unit for very sick patients....

Ruthbaby - 29 Mar 2017 08:10 - 63 of 71

Someone posted the presentation on another bb
https://www.sharesmagazine.co.uk/video/dr-wolfgang-rencken-ceo-of-sphere-medical-sphr-2
  • Page:
  • 1
  • 2
  • 3
  • 4
Register now or login to post to this thread.